Rapport Therapeutics (RAPP) Current Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Current Assets data on file, last reported at $484.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $484.7 million, up 66.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $484.7 million (up 66.58% YoY), and the FY2025 annual result was $498.6 million, up 60.93% from the prior year.
• Current Assets eased to $484.7 million in Q1 2026 per RAPP's latest filing, from $498.6 million in the prior quarter.
• Over five years, Current Assets peaked at $520.7 million in Q3 2025 and troughed at $150.9 million in Q4 2023.
• A 4-year average of $354.7 million and a median of $325.9 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets soared 105.34% in 2024, then declined 20.67% in 2025.
• A 4-year view of Current Assets shows it stood at $150.9 million in 2023, then surged by 105.34% to $309.8 million in 2024, then jumped by 60.93% to $498.6 million in 2025, then declined by 2.78% to $484.7 million in 2026.
• Business Quant data shows RAPP's Current Assets at $484.7 million in Q1 2026, $498.6 million in Q4 2025, and $520.7 million in Q3 2025.